Conference Presentation, Panel, Fireside Chat
Young Entrepreneurs Who Are Rewriting the Biopharma Business Model
- Automated DNA sequencing is expected to become faster, better, and cheaper, while biological communications technologies remain 100 years away.
- The pharmaceutical business model faces a multi-year fundamental challenge, with drug discovery shifting toward large-scale data analysis and integration of over 2 million publicly available gene expression datasets doubling annually.
- A new "cloud computing of biotech" business model is predicted to emerge, potentially making drug development more predictive, lower-risk, lower-cost, and faster by reducing friction and enabling instant access to global experts.
- Science Exchange is forecast to significantly reduce qualification and contracting friction, with the number of user companies expected to rise substantially next year.
- Verge Genomics plans to streamline R&D by co-locating computer scientists, biologists, and drug development veterans, while investors anticipate growth as software transformation is demonstrated.
- The sector is facing an oversupply of life science PhDs relative to academic positions, driving a generation of trainees toward entrepreneurship as primary paths outside traditional academia.
- Critical bottlenecks in turning data into knowledge include the siloing of computer scientists and biologists, a shortage of talent capable of integrating data to single gene targets, and slow university curriculum reforms.
- Data integration remains difficult in the U.S. due to medical record silos, though unique assets like the Icelandic population dataset may gain value.
- Biological engineering is expected to fundamentally revolutionize disease treatment and health perspectives within the current decade, with significant shifts in other areas potentially occurring over a 50-year transition.
- Organ-on-a-chip technologies are expected to address high testing costs by providing reliable, repeatable alternatives to human subjects and often non-reproducible animal models.
- Venture philanthropy and nontraditional funding sources are projected to democratize, with patient groups forming LLCs and mobilizing funds for risky innovation.
- Government entities, including the NIH, DARPA, and potentially the government at large, are expected to fund risky innovation, with NIH SBIR rules modified to better support venture-backed companies.
- Pharmaceutical companies risk a trajectory toward disaster if R&D productivity continues to decline and innovation costs rise, necessitating systems to develop young ideas into sustainable pipelines.
- Big Pharma is expected to play a decisive role in providing liquidity for employees and must collaborate closely with the NIH to ensure long-term funding stability.
- Public benefit corporations (PBCs) are anticipated to flourish in the pharma space to balance social missions with profitability beyond current examples like Trek Therapeutics.
- Silicon Valley's culture of investing and data science is expected to continue influencing biotech, offering a canvas for creative PhDs despite potential disappointments.
- Biotech companies face continued conservatism from venture capital and big pharma regarding the age and appearance of founders.
- Patient advocates are expected to mobilize online to form disease communities, creating "economies of rare" and finding researchers more effectively.
- Health and life sciences are predicted to see the most important changes over the next several decades, requiring significant innovation in business models and delivery systems to address "people problems."
- The number of job candidates with coding and analysis skills is expected to increase, though the graduate institution level remains the primary constraint on talent availability.